{"protocolSection":{"identificationModule":{"nctId":"NCT02973100","orgStudyIdInfo":{"id":"16568"},"secondaryIdInfos":[{"id":"H9X-MC-GBGJ","type":"OTHER","domain":"Eli Lilly and Company"},{"id":"2016-002494-34","type":"EUDRACT_NUMBER"},{"id":"2016","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2016"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy","officialTitle":"A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy"},"statusModule":{"statusVerifiedDate":"2019-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-12"},"primaryCompletionDateStruct":{"date":"2017-07-15","type":"ACTUAL"},"completionDateStruct":{"date":"2017-08-14","type":"ACTUAL"},"studyFirstSubmitDate":"2016-11-22","studyFirstSubmitQcDate":"2016-11-22","studyFirstPostDateStruct":{"date":"2016-11-25","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-07-13","resultsFirstSubmitQcDate":"2018-08-22","resultsFirstPostDateStruct":{"date":"2018-08-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-09-05","lastUpdatePostDateStruct":{"date":"2019-09-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the efficacy and safety of investigational doses of dulaglutide in participants with type 2 diabetes on metformin monotherapy."},"conditionsModule":{"conditions":["Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":318,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Dulaglutide 4.5mg","type":"EXPERIMENTAL","description":"4.5mg of Dulaglutide administered subcutaneously (SC)","interventionNames":["Drug: Dulaglutide"]},{"label":"Dulaglutide 3.0mg","type":"EXPERIMENTAL","description":"3.0mg of Dulaglutide administered SC","interventionNames":["Drug: Dulaglutide"]},{"label":"Dulaglutide 1.5mg","type":"ACTIVE_COMPARATOR","description":"1.5mg of Dulaglutide administered SC","interventionNames":["Drug: Dulaglutide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo administered SC","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Dulaglutide","description":"Administered SC","armGroupLabels":["Dulaglutide 1.5mg","Dulaglutide 3.0mg","Dulaglutide 4.5mg"],"otherNames":["LY2189265"]},{"type":"DRUG","name":"Placebo","description":"Administered SC","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c)","description":"HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.\n\nLeast Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline as a covariate, pooled country, treatment, time, treatment\\*time as fixed effects.","timeFrame":"Baseline, Week 18"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With HbA1c of <7.0%","description":"Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.","timeFrame":"Week 18"},{"measure":"Change From Baseline in Fasting Serum Glucose (FSG)","description":"Fasting serum glucose (FSG) is a test to determine how much glucose (sugar) is in a serum sample after an overnight fast. Least Squares (LS) means was determined by MMRM methodology with baseline as a covariate, pooled country, baseline HbA1c strata using \\>=8% as cutoff, treatment, time, treatment\\*time as fixed effects.","timeFrame":"Baseline, Week 18"},{"measure":"Change From Baseline in Body Weight","description":"Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline as a covariate, pooled country, baseline HbA1c strata using \\>=8% as cutoff, treatment, time, treatment\\*time as fixed effects.","timeFrame":"Baseline, Week 18"},{"measure":"Percentage of Participants Discontinuing Study Drug Due to Adverse Events","description":"Adverse event (AE) defined as any unfavorable medical event, newly emerged or a deterioration of a preexisting condition, in other words any untoward medical occurrence in a patient administered a pharmaceutical product, without regard to the possibility of a causal relationship, that occurred after the visit for informed consent and up to the visit for completion of administration, or discontinuation.","timeFrame":"Baseline through Week 18"},{"measure":"Rate of Documented Symptomatic Hypoglycemia","description":"Hypoglycemic events (HE) were classified as severe, documented symptomatic (defined as an HE with typical symptoms of hypoglycemia and a blood glucose level of ≤3.9 millimoles per liter \\[mmol/L\\]). Hypoglycemia rate per 30 days was summarized at each visit by treatment group. The rate of hypoglycemia was analyzed using a generalized estimation equations model with a negative binomial distribution and a Log link. LS mean was determined by MMRM methodology with baseline hypoglycemia rate, pooled country, HbA1c at Baseline, treatment, with log of exposure in days divided by 365.25 as the offset.","timeFrame":"Week 18"},{"measure":"Pharmacokinetics (PK): The Maximum Drug Concentration at Steady State (Cmax,ss) of Dulaglutide","description":"Plasma samples for PK analysis were combined measure obtained from 0, 2, 4, 6, 10, 18, 22 weeks and until early termination of the visit. Cmax takes all time points post dose into account and one value was reported.","timeFrame":"0, 2, 4, 6, 10, 18, 22 weeks and early termination"},{"measure":"Pharmacokinetics: Area Under the Concentration-Time Curve at Steady State From Time Zero to 168 Hours (AUC[0-168], ss) of Dulaglutide","description":"AUC\\[0-168h\\] is a combined measure obtained from 0, 2, 4, 6, 10, 18, 22 weeks and until early termination of the visit.","timeFrame":"0, 2, 4, 6, 10, 18, 22 weeks and early termination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have had type 2 diabetes (T2D) for ≥6 months according to the World Health Organization (WHO) classification\n* Have HbA1c of 7.0% to 10.0%, inclusive, as assessed by the central laboratory\n* Have been treated with stable doses of metformin for at least 3 months\n* Have a body mass index (BMI) ≥25 kilograms per square meter\n\nExclusion Criteria:\n\n* Have type 1 diabetes (T1D)\n* Have used any glucose-lowering medication other than metformin 3 months prior to study entry or during screening/lead-in period or have used any glucagon-like peptide-1 receptor agonists (GLP-1 RAs) at any time in the past\n* Have had any of the following cardiovascular conditions: acute myocardial infarction (MI), New York Heart Association Class III or Class IV heart failure, or cerebrovascular accident (stroke)\n* Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or alanine aminotransferase (ALT) level \\>2.5 times the upper limit of the reference range, as determined by the central laboratory at study entry; participants with NAFLD are eligible for participation in this trial\n* Have had chronic or acute pancreatitis any time prior to study entry\n* Have an estimated glomerular filtration rate (eGFR) \\<45 milliliters/minute/1.73 square meter, calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation\n* Have serum calcitonin ≥20 picograms per milliliter, as determined by the central laboratory at study entry","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Parexel Early Phase Unit at Glendale","city":"Glendale","state":"California","zip":"91206-4140","country":"United States","geoPoint":{"lat":34.14251,"lon":-118.25508}},{"facility":"Marin Endocrine Associates","city":"Greenbrae","state":"California","zip":"94904","country":"United States","geoPoint":{"lat":37.94854,"lon":-122.5247}},{"facility":"National Research Institute","city":"Huntington Park","state":"California","zip":"90255","country":"United States","geoPoint":{"lat":33.98168,"lon":-118.22507}},{"facility":"National Research Institute","city":"Los Angeles","state":"California","zip":"90057","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Catalina Research Institute, LLC","city":"Montclair","state":"California","zip":"91763","country":"United States","geoPoint":{"lat":34.07751,"lon":-117.68978}},{"facility":"Artemis Institute for Clinical Research","city":"San Diego","state":"California","zip":"92103","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Encompass Clinical Research","city":"Spring Valley Lake","state":"California","zip":"91978","country":"United States","geoPoint":{"lat":34.49364,"lon":-117.26832}},{"facility":"University Clinical Investigators, Inc.","city":"Tustin","state":"California","zip":"92780","country":"United States","geoPoint":{"lat":33.74585,"lon":-117.82617}},{"facility":"Infosphere","city":"Van Nuys","state":"California","zip":"91405","country":"United States","geoPoint":{"lat":34.18667,"lon":-118.44897}},{"facility":"Diablo Clinical Research","city":"Walnut Creek","state":"California","zip":"94598","country":"United States","geoPoint":{"lat":37.90631,"lon":-122.06496}},{"facility":"Chase Medical Research, LLC","city":"Waterbury","state":"Connecticut","zip":"06708","country":"United States","geoPoint":{"lat":41.55815,"lon":-73.0515}},{"facility":"Axes Medical Research, LLC","city":"Cooper City","state":"Florida","zip":"33024","country":"United States","geoPoint":{"lat":26.05731,"lon":-80.27172}},{"facility":"Clinical Research of South Florida","city":"Coral Gables","state":"Florida","zip":"33134","country":"United States","geoPoint":{"lat":25.72149,"lon":-80.26838}},{"facility":"East Coast Institute For Research","city":"Jacksonville","state":"Florida","zip":"32204","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"New Horizon Research Center","city":"Miami","state":"Florida","zip":"33175","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Suncoast Research Group, LLC","city":"Miami Lakes","state":"Florida","zip":"33135","country":"United States","geoPoint":{"lat":25.90871,"lon":-80.30866}},{"facility":"Palm Harbor Medical Associates","city":"Palm Harbor","state":"Florida","zip":"34684","country":"United States","geoPoint":{"lat":28.07807,"lon":-82.76371}},{"facility":"In-Quest Medical Research, LLC - Norcross","city":"Norcross","state":"Georgia","zip":"30071","country":"United States","geoPoint":{"lat":33.94121,"lon":-84.21353}},{"facility":"East West Medical Institute","city":"Honolulu","state":"Hawaii","zip":"96814","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"facility":"Elite Cilnical Trials LLLP","city":"Blackfoot","state":"Idaho","zip":"83221","country":"United States","geoPoint":{"lat":43.19047,"lon":-112.34498}},{"facility":"Solaris Clinical Research","city":"Meridian","state":"Idaho","zip":"83646","country":"United States","geoPoint":{"lat":43.61211,"lon":-116.39151}},{"facility":"HSHS Medical Group Diabetes Research","city":"Springfield","state":"Illinois","zip":"62711","country":"United States","geoPoint":{"lat":39.80172,"lon":-89.64371}},{"facility":"American Health Network","city":"Indianapolis","state":"Indiana","zip":"46254","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"Iderc, P.L.C.","city":"Des Moines","state":"Iowa","zip":"50314","country":"United States","geoPoint":{"lat":41.60054,"lon":-93.60911}},{"facility":"Cotton O'Neil Diabetes and Endocrinology Center","city":"Topeka","state":"Kansas","zip":"66606","country":"United States","geoPoint":{"lat":39.04833,"lon":-95.67804}},{"facility":"ActivMed Practices & Research, Inc","city":"Methuen","state":"Massachusetts","zip":"01844","country":"United States","geoPoint":{"lat":42.7262,"lon":-71.19089}},{"facility":"StudyMetrix Research, LLC","city":"City of Saint Peters","state":"Missouri","zip":"63303","country":"United States","geoPoint":{"lat":38.80033,"lon":-90.62651}},{"facility":"Manhattan Medical Research","city":"New York Mills","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":43.10535,"lon":-75.29128}},{"facility":"High Point Clinical Trials Center","city":"High Point","state":"North Carolina","zip":"27265","country":"United States","geoPoint":{"lat":35.95569,"lon":-80.00532}},{"facility":"Aventiv Research","city":"Columbus","state":"Ohio","zip":"43213","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"The Corvallis Clinic P.C.","city":"Corvallis","state":"Oregon","zip":"97330","country":"United States","geoPoint":{"lat":44.56457,"lon":-123.26204}},{"facility":"Heritage Valley Medical Group, Inc.","city":"Beaver","state":"Pennsylvania","zip":"15009","country":"United States","geoPoint":{"lat":40.69534,"lon":-80.30478}},{"facility":"New Phase Research & Development","city":"Knoxville","state":"Tennessee","zip":"37909","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Dallas Diabetes Endocrine Center","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Consano Clinical Research","city":"San Antonio","state":"Texas","zip":"78231","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Clinpoint Trial, LLC","city":"Waxahachie","state":"Texas","zip":"75165","country":"United States","geoPoint":{"lat":32.38653,"lon":-96.84833}},{"facility":"Chrysalis Clinical Research","city":"St. George","state":"Utah","zip":"84790","country":"United States","geoPoint":{"lat":37.10415,"lon":-113.58412}},{"facility":"Rainier Clinical Research Center","city":"Renton","state":"Washington","zip":"98057","country":"United States","geoPoint":{"lat":47.48288,"lon":-122.21707}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Brandýs nad Labem-Stará Boleslav","zip":"25001","country":"Czechia","geoPoint":{"lat":50.18709,"lon":14.66326}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Krnov","zip":"79401","country":"Czechia","geoPoint":{"lat":50.08967,"lon":17.70385}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Prague","zip":"11000","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Prague","zip":"149 00","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Prague","zip":"181 00","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Praha 4 - Krc","zip":"140 59","country":"Czechia"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chihuahua City","zip":"31217","country":"Mexico","geoPoint":{"lat":28.63528,"lon":-106.08889}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cuernavaca","zip":"62250","country":"Mexico","geoPoint":{"lat":18.9261,"lon":-99.23075}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Guadalajara","zip":"04460","country":"Mexico","geoPoint":{"lat":20.67738,"lon":-103.34749}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Monterrey","zip":"64460","country":"Mexico","geoPoint":{"lat":25.68435,"lon":-100.31721}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tampico","zip":"89000","country":"Mexico","geoPoint":{"lat":22.28519,"lon":-97.87777}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bialystok","zip":"15-404","country":"Poland","geoPoint":{"lat":53.13333,"lon":23.16433}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bialystok","zip":"15-445","country":"Poland","geoPoint":{"lat":53.13333,"lon":23.16433}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Gdansk","zip":"80-546","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lodz","zip":"90-242","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lublin","zip":"20-333","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lublin","zip":"20-538","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Poznan","zip":"61-655","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Poznan","zip":"61-853","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ruda Śląska","zip":"41-709","country":"Poland","geoPoint":{"lat":50.2584,"lon":18.85632}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Szczecin","zip":"70-506","country":"Poland","geoPoint":{"lat":53.42894,"lon":14.55302}},{"facility":"Marginal Doctor's Center","city":"Manati","zip":"00674","country":"Puerto Rico","geoPoint":{"lat":18.42745,"lon":-66.49212}},{"facility":"American Telemedicine Center","city":"San Juan","zip":"00917","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Alba Iulia","zip":"510053","country":"Romania","geoPoint":{"lat":46.06667,"lon":23.58333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Baia Mare","zip":"430222","country":"Romania","geoPoint":{"lat":47.65729,"lon":23.56808}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Iași","zip":"700547","country":"Romania","geoPoint":{"lat":47.16667,"lon":27.6}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Oradea","zip":"410159","country":"Romania","geoPoint":{"lat":47.0458,"lon":21.91833}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Satu Mare","zip":"440055","country":"Romania","geoPoint":{"lat":47.79926,"lon":22.86255}}]},"referencesModule":{"seeAlsoLinks":[{"label":"A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy","url":"https://www.lillytrialguide.com/en-US/studies/type-2-diabetes/GBGJ#?postal="}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.","accessCriteria":"A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.","url":"https://vivli.org/"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"The study consisted of 3 periods: an approximately 2-week lead-in period, followed by an 18-week treatment period, and a 4-week safety follow-up period.","groups":[{"id":"FG000","title":"Placebo","description":"Participants received placebo once weekly (QW) by subcutaneous (SC) injection."},{"id":"FG001","title":"Dulaglutide 1.5 Milligrams (mg)","description":"Participants received 1.5mg of dulaglutide QW by SC injection."},{"id":"FG002","title":"Dulaglutide 3.0mg","description":"Participants received 3.0mg of dulaglutide QW by SC injection."},{"id":"FG003","title":"Dulaglutide 4.5mg","description":"Participants received 4.5mg of dulaglutide QW by SC injection."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"82"},{"groupId":"FG001","numSubjects":"81"},{"groupId":"FG002","numSubjects":"79"},{"groupId":"FG003","numSubjects":"76"}]},{"type":"Received at Least 1 Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"81"},{"groupId":"FG001","numSubjects":"81"},{"groupId":"FG002","numSubjects":"79"},{"groupId":"FG003","numSubjects":"76"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"75"},{"groupId":"FG001","numSubjects":"73"},{"groupId":"FG002","numSubjects":"75"},{"groupId":"FG003","numSubjects":"69"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"7"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"4"}]},{"type":"Notification of change in address","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Failed to attend Safety followup period","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Placebo","description":"Participants received placebo once weekly (QW) by subcutaneous (SC) injection."},{"id":"BG001","title":"Dulaglutide 1.5mg","description":"Participants received 1.5mg of dulaglutide QW by SC injection."},{"id":"BG002","title":"Dulaglutide 3.0mg","description":"Participants received 3.0mg of dulaglutide QW by SC injection."},{"id":"BG003","title":"Dulaglutide 4.5mg","description":"Participants received 4.5mg of dulaglutide QW by SC injection."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"81"},{"groupId":"BG002","value":"79"},{"groupId":"BG003","value":"76"},{"groupId":"BG004","value":"317"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56.52","spread":"8.93"},{"groupId":"BG001","value":"57.65","spread":"9.79"},{"groupId":"BG002","value":"55.90","spread":"10.74"},{"groupId":"BG003","value":"57.13","spread":"9.63"},{"groupId":"BG004","value":"56.80","spread":"9.77"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"44"},{"groupId":"BG003","value":"40"},{"groupId":"BG004","value":"159"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"35"},{"groupId":"BG003","value":"36"},{"groupId":"BG004","value":"158"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"38"},{"groupId":"BG003","value":"30"},{"groupId":"BG004","value":"135"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"45"},{"groupId":"BG004","value":"180"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"31"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"4"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"24"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"58"},{"groupId":"BG003","value":"59"},{"groupId":"BG004","value":"244"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"12"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Romania","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"21"}]}]},{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"44"},{"groupId":"BG003","value":"43"},{"groupId":"BG004","value":"174"}]}]},{"title":"Czechia","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"37"}]}]},{"title":"Poland","categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"44"}]}]},{"title":"Mexico","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"41"}]}]}]},{"title":"Baseline Hemoglobin A1c (HbA1c)","description":"HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Percentage of glycosylated hemoglobin","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8.08","spread":"0.79"},{"groupId":"BG001","value":"8.02","spread":"0.80"},{"groupId":"BG002","value":"8.16","spread":"0.92"},{"groupId":"BG003","value":"8.12","spread":"0.81"},{"groupId":"BG004","value":"8.09","spread":"0.83"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (HbA1c)","description":"HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.\n\nLeast Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline as a covariate, pooled country, treatment, time, treatment\\*time as fixed effects.","populationDescription":"All randomized participants who received at least one dose of study drug and had postbaseline values, excluding post rescue data for Hemoglobin A1c.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percentage of glycosylated hemoglobin","timeFrame":"Baseline, Week 18","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo once weekly (QW) by subcutaneous (SC) injection."},{"id":"OG001","title":"Dulaglutide 1.5mg","description":"Participants received 1.5mg of dulaglutide QW by SC injection."},{"id":"OG002","title":"Dulaglutide 3.0mg","description":"Participants received 3.0mg of dulaglutide QW by SC injection."},{"id":"OG003","title":"Dulaglutide 4.5mg","description":"Participants received 4.5mg of dulaglutide QW by SC injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"73"},{"groupId":"OG003","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":"0.101"},{"groupId":"OG001","value":"-1.23","spread":"0.099"},{"groupId":"OG002","value":"-1.31","spread":"0.099"},{"groupId":"OG003","value":"-1.40","spread":"0.103"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<.001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-0.80","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.07","ciUpperLimit":"-0.53"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-0.87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.14","ciUpperLimit":"-0.60"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<.001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-0.96","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.24","ciUpperLimit":"-0.69"}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c of <7.0%","description":"Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.","populationDescription":"All randomized participants who received at least one dose of study drug and had postbaseline values, excluding post rescue data for Hemoglobin A1c.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Week 18","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo once weekly (QW) by subcutaneous (SC) injection."},{"id":"OG001","title":"Dulaglutide 1.5mg","description":"Participants received 1.5mg of dulaglutide QW by SC injection."},{"id":"OG002","title":"Dulaglutide 3.0mg","description":"Participants received 3.0mg of dulaglutide QW by SC injection."},{"id":"OG003","title":"Dulaglutide 4.5mg","description":"Participants received 4.5mg of dulaglutide QW by SC injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"73"},{"groupId":"OG003","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"71.2"},{"groupId":"OG002","value":"71.2"},{"groupId":"OG003","value":"68.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"24.489","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"8.368","ciUpperLimit":"71.667"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"27.906","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"9.238","ciUpperLimit":"84.300"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"21.852","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"7.672","ciUpperLimit":"62.242"}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Serum Glucose (FSG)","description":"Fasting serum glucose (FSG) is a test to determine how much glucose (sugar) is in a serum sample after an overnight fast. Least Squares (LS) means was determined by MMRM methodology with baseline as a covariate, pooled country, baseline HbA1c strata using \\>=8% as cutoff, treatment, time, treatment\\*time as fixed effects.","populationDescription":"All randomized participants who received at least one dose of study drug and had postbaseline values, excluding post rescue data for FSG.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"millimole/liter (mmol/L)","timeFrame":"Baseline, Week 18","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo once weekly (QW) by subcutaneous (SC) injection."},{"id":"OG001","title":"Dulaglutide 1.5mg","description":"Participants received 1.5mg of dulaglutide QW by SC injection."},{"id":"OG002","title":"Dulaglutide 3.0mg","description":"Participants received 3.0mg of dulaglutide QW by SC injection."},{"id":"OG003","title":"Dulaglutide 4.5mg","description":"Participants received 4.5mg of dulaglutide QW by SC injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"62"},{"groupId":"OG002","value":"67"},{"groupId":"OG003","value":"61"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.69","spread":"0.257"},{"groupId":"OG001","value":"-2.01","spread":"0.261"},{"groupId":"OG002","value":"-1.92","spread":"0.250"},{"groupId":"OG003","value":"-2.11","spread":"0.263"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-1.32","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.02","ciUpperLimit":"-0.62"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-1.23","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.91","ciUpperLimit":"-0.54"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-1.42","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.12","ciUpperLimit":"-0.72"}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight","description":"Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline as a covariate, pooled country, baseline HbA1c strata using \\>=8% as cutoff, treatment, time, treatment\\*time as fixed effects.","populationDescription":"All randomized participants who received at least one dose of study drug and had postbaseline values, excluding post rescue data for body weight.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Kilograms (Kg)","timeFrame":"Baseline, Week 18","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo once weekly (QW) by subcutaneous (SC) injection."},{"id":"OG001","title":"Dulaglutide 1.5mg","description":"Participants received 1.5mg of dulaglutide QW by SC injection."},{"id":"OG002","title":"Dulaglutide 3.0mg","description":"Participants received 3.0mg of dulaglutide QW by SC injection."},{"id":"OG003","title":"Dulaglutide 4.5mg","description":"Participants received 4.5mg of dulaglutide QW by SC injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"74"},{"groupId":"OG003","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"0.39"},{"groupId":"OG001","value":"-2.8","spread":"0.39"},{"groupId":"OG002","value":"-3.9","spread":"0.39"},{"groupId":"OG003","value":"-4.1","spread":"0.41"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.025","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-1.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.3","ciUpperLimit":"-0.2"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-2.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.4","ciUpperLimit":"-1.3"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-2.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.7","ciUpperLimit":"-1.5"}]},{"type":"SECONDARY","title":"Percentage of Participants Discontinuing Study Drug Due to Adverse Events","description":"Adverse event (AE) defined as any unfavorable medical event, newly emerged or a deterioration of a preexisting condition, in other words any untoward medical occurrence in a patient administered a pharmaceutical product, without regard to the possibility of a causal relationship, that occurred after the visit for informed consent and up to the visit for completion of administration, or discontinuation.","populationDescription":"All randomized participants who received study drug and had postbaseline data for safety analyses.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Baseline through Week 18","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo once weekly (QW) by subcutaneous (SC) injection."},{"id":"OG001","title":"Dulaglutide 1.5mg","description":"Participants received 1.5mg of dulaglutide QW by SC injection."},{"id":"OG002","title":"Dulaglutide 3.0mg","description":"Participants received 3.0mg of dulaglutide QW by SC injection."},{"id":"OG003","title":"Dulaglutide 4.5mg","description":"Participants received 4.5mg of dulaglutide QW by SC injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"81"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"76"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9"},{"groupId":"OG001","value":"6.2"},{"groupId":"OG002","value":"10.1"},{"groupId":"OG003","value":"13.2"}]}]}]},{"type":"SECONDARY","title":"Rate of Documented Symptomatic Hypoglycemia","description":"Hypoglycemic events (HE) were classified as severe, documented symptomatic (defined as an HE with typical symptoms of hypoglycemia and a blood glucose level of ≤3.9 millimoles per liter \\[mmol/L\\]). Hypoglycemia rate per 30 days was summarized at each visit by treatment group. The rate of hypoglycemia was analyzed using a generalized estimation equations model with a negative binomial distribution and a Log link. LS mean was determined by MMRM methodology with baseline hypoglycemia rate, pooled country, HbA1c at Baseline, treatment, with log of exposure in days divided by 365.25 as the offset.","populationDescription":"All randomized participants who received at least one dose of study drug and had postbaseline values, excluding post rescue values for hypoglycemic episodes.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Episodes/participant/365.25 days","timeFrame":"Week 18","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo once weekly (QW) by subcutaneous (SC) injection."},{"id":"OG001","title":"Dulaglutide 1.5mg","description":"Participants received 1.5mg of dulaglutide QW by SC injection."},{"id":"OG002","title":"Dulaglutide 3.0mg","description":"Participants received 3.0mg of dulaglutide QW by SC injection."},{"id":"OG003","title":"Dulaglutide 4.5mg","description":"Participants received 4.5mg of dulaglutide QW by SC injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"81"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"76"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"},{"groupId":"OG001","value":"0.00","spread":"0.000"},{"groupId":"OG002","value":"0.00","spread":"0.000"},{"groupId":"OG003","value":"0.00","spread":"0.001"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics (PK): The Maximum Drug Concentration at Steady State (Cmax,ss) of Dulaglutide","description":"Plasma samples for PK analysis were combined measure obtained from 0, 2, 4, 6, 10, 18, 22 weeks and until early termination of the visit. Cmax takes all time points post dose into account and one value was reported.","populationDescription":"All randomized participants who received at least one dose of the study drug and have evaluable PK data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"nanogram per milliliter (ng/mL)","timeFrame":"0, 2, 4, 6, 10, 18, 22 weeks and early termination","groups":[{"id":"OG000","title":"Dulaglutide 1.5mg","description":"Participants received 1.5mg of dulaglutide QW by SC injection."},{"id":"OG001","title":"Dulaglutide 3.0mg","description":"Participants received 3.0mg of dulaglutide QW by SC injection."},{"id":"OG002","title":"Dulaglutide 4.5mg","description":"Participants received 4.5mg of dulaglutide QW by SC injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"76"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.4","lowerLimit":"38.9","upperLimit":"170"},{"groupId":"OG001","value":"151","lowerLimit":"64.3","upperLimit":"277"},{"groupId":"OG002","value":"204","lowerLimit":"87.2","upperLimit":"377"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Area Under the Concentration-Time Curve at Steady State From Time Zero to 168 Hours (AUC[0-168], ss) of Dulaglutide","description":"AUC\\[0-168h\\] is a combined measure obtained from 0, 2, 4, 6, 10, 18, 22 weeks and until early termination of the visit.","populationDescription":"All randomized participants who received at least one dose of the study drug and have evaluable PK data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"nanogram*hour per milliliter (ng*h/mL)","timeFrame":"0, 2, 4, 6, 10, 18, 22 weeks and early termination","groups":[{"id":"OG000","title":"Dulaglutide 1.5mg","description":"Participants received 1.5mg of dulaglutide QW by SC injection."},{"id":"OG001","title":"Dulaglutide 3.0mg","description":"Participants received 3.0mg of dulaglutide QW by SC injection."},{"id":"OG002","title":"Dulaglutide 4.5mg","description":"Participants received 4.5mg of dulaglutide QW by SC injection."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"76"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11800","lowerLimit":"5300","upperLimit":"21300"},{"groupId":"OG001","value":"26700","lowerLimit":"15300","upperLimit":"41400"},{"groupId":"OG002","value":"36600","lowerLimit":"21100","upperLimit":"56500"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to 22 weeks","description":"All participants who received at least one dose of study drug.","eventGroups":[{"id":"EG000","title":"Placebo","description":"Participants received placebo once weekly (QW) by subcutaneous (SC) injection.","deathsNumAffected":0,"deathsNumAtRisk":81,"seriousNumAffected":4,"seriousNumAtRisk":81,"otherNumAffected":29,"otherNumAtRisk":81},{"id":"EG001","title":"Dulaglutide 1.5mg","description":"Participants received 1.5mg of dulaglutide QW by SC injection.","deathsNumAffected":0,"deathsNumAtRisk":81,"seriousNumAffected":3,"seriousNumAtRisk":81,"otherNumAffected":36,"otherNumAtRisk":81},{"id":"EG002","title":"Dulaglutide 3.0mg","description":"Participants received 3.0mg of dulaglutide QW by SC injection.","deathsNumAffected":0,"deathsNumAtRisk":79,"seriousNumAffected":7,"seriousNumAtRisk":79,"otherNumAffected":49,"otherNumAtRisk":79},{"id":"EG003","title":"Dulaglutide 4.5mg","description":"Participants received 4.5mg of dulaglutide QW by SC injection.","deathsNumAffected":0,"deathsNumAtRisk":76,"seriousNumAffected":3,"seriousNumAtRisk":76,"otherNumAffected":39,"otherNumAtRisk":76}],"seriousEvents":[{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Atrioventricular block second degree","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":81},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":81},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":76}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":76}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":76}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":76}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":81},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":76}]},{"term":"Cholecystitis infective","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Fungal oesophagitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Peritonsillar abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Traumatic intracranial haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Hyperglycaemic hyperosmolar nonketotic syndrome","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Hypovolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Spinal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Invasive ductal breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]}],"otherEvents":[{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":79},{"groupId":"EG003","numEvents":10,"numAffected":4,"numAtRisk":76}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":81},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":81},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":76}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":81},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":79},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":76}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":81},{"groupId":"EG001","numEvents":17,"numAffected":9,"numAtRisk":81},{"groupId":"EG002","numEvents":34,"numAffected":18,"numAtRisk":79},{"groupId":"EG003","numEvents":32,"numAffected":16,"numAtRisk":76}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":10,"numAffected":6,"numAtRisk":81},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":79},{"groupId":"EG003","numEvents":13,"numAffected":8,"numAtRisk":76}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":81},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":76}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":81},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":81},{"groupId":"EG001","numEvents":45,"numAffected":18,"numAtRisk":81},{"groupId":"EG002","numEvents":32,"numAffected":20,"numAtRisk":79},{"groupId":"EG003","numEvents":40,"numAffected":23,"numAtRisk":76}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":81},{"groupId":"EG001","numEvents":20,"numAffected":9,"numAtRisk":81},{"groupId":"EG002","numEvents":15,"numAffected":9,"numAtRisk":79},{"groupId":"EG003","numEvents":16,"numAffected":10,"numAtRisk":76}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":81},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":81},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":79},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":76}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":81},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":79},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":76}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":81},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":81},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":79},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":76}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":81},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":81},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":79},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":76}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG001","numEvents":6,"numAffected":3,"numAtRisk":81},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":79},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":76}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":81},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":81},{"groupId":"EG002","numEvents":17,"numAffected":13,"numAtRisk":79},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":76}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":81},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":81},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":79},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":76}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":81},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":81},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":79},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":76}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":7,"numAtRisk":81},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":81},{"groupId":"EG002","numEvents":13,"numAffected":10,"numAtRisk":79},{"groupId":"EG003","numEvents":8,"numAffected":5,"numAtRisk":76}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":81},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":81},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":79},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":76}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"800-545-5979"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2016-12-08","uploadDate":"2018-05-08T03:11","filename":"SAP_000.pdf","size":774140},{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2016-11-07","uploadDate":"2018-08-13T01:01","filename":"Prot_001.pdf","size":841762}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C555680","term":"dulaglutide"}]}},"hasResults":true}